Clinical trial
A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA)…
NCT01432145 · University of Oxford, Other · Completed
Key facts
| NCT number | NCT01432145 |
|---|---|
| Title | A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours |
| Official title | Phase II Clinical Trial Of 6-Mercaptopurine (6MP) and Low-Dose Methotrexate In Patients With Known BRCA Defective Tumours |
| Acronym | 6MP |
| Lead sponsor | University of Oxford, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Ovarian Cancer |
| Intervention type | Drug |
| Interventions | 6-Mercaptopurine, Methotrexate |
| Enrollment | 74 |
| Start date | May 1, 2011 |
| Primary completion | Dec 1, 2014 |
| Completion | May 1, 2015 |
| First posted | Sep 12, 2011 |
| Last update posted | Jul 9, 2019 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: